in Newswire Published on January 19, 2022

NRx Pharmaceuticals Withheld COVID-19 Drug Approval Info from Investors, Class Action Alleges

Dal Bosco v. NRx Pharmaceuticals, Inc. et al.

Filed: January 18, 2022 § 1:22-cv-00066

A class action alleges NRx Pharmaceuticals was not forthcoming to investors with regard to the prospects of a purported COVID-19 treatment being approved for emergency use.

State(s)

Delaware

Case Spotlight

Camp Lejeune

ClassAction.org Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on January 19, 2022 — 4:30 PM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Senior Managing Editor of ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.